Over 50 years ago, von Euler confirmed the identity of noradrenaline as the neurotransmitter released from sympathetic nerve terminals. With time, however, it became apparent that not all the effects of autonomic nerve stimulation could be accounted for by the actions of noradrenaline and acetylcholine, and this led to the concept of 'non-adrenergic and non-cholinergic' autonomic neurotransmission. Subsequently, it was proposed that ATP might act alongside noradrenaline and acetylcholine as a neurotransmitter released from autonomic postganglionic neurons [1] .
At first, this 'purinergic' hypothesis was not universally accepted. But the weight of evidence has grown over the years, with the demonstration of inter-neuronal purinergic synapses in the brain [2] and myenteric ganglia [3] , and the cloning of specific purinergic receptors (see [4] for review). Nevertheless, the physiological importance of the purinergic component of co-transmission is not always clear. The latest findings from the work of Mulryan et al. [5] have provided hard evidence for an important physiological role for purinergic transmission, at least in the vas deferens of the mouse. They have demonstrated that purinergic neurotransmission in the vas deferens plays a vital role during copulation, ensuring high numbers of sperm are incorporated into the semen prior to ejaculation.
A major problem in demonstrating purinergic co-transmission conclusively has been the lack of potent and selective antagonists. Mulryan et al. [5] circumvented this problem by using genetic manipulation to produce 'knockout' mice lacking the gene for the P2X 1 receptor. The only apparent effect of this gene deletion was a 90% reduction in the fertility of the male animals, which resulted from a low sperm count in the ejaculated semen. Thus mutant females did not become pregnant when mated with mutant males, but normal rates of conception were observed when they mated with wild-type or heterozygous males.
The sperm from the mutant male mice were, however, viable and able to fertilize ova in vitro. Mulryan et al. [5] have therefore suggested that the selective pharmacological blockade of P2X 1 receptors should produce a similar effect, and might thus provide the means for developing a non-hormonal male contraceptive pill. If this approach is successful, treatment could be effective in days or even hours, unlike the protracted hormonal treatments at present under evaluation [6] . Indeed, one could envisage a product, perhaps a sublingual tablet or spray, which would produce its effect within 30 minutes and could thus be used on an 'as required' basis in a similar way to the anti impotence drug Viagra.
The vas deferens is responsible for both the storage of mature spermatazoa and for dispensing sperm into the urethra to be combined with the other components of semen prior to ejaculation. Stimulation of the vas deferens with a train of electrial pulses gives rise to a biphasic contraction, consisting of an initial transient component which declines to a more sustained plateau. The sustained component of the response is blocked by α-adrenoceptor antagonists, such as prazosin, while the transient component is abolished by α,β-methylene-ATP, which acts to desensitize the purinergic P2X receptors ( Figure 1 ). The combination of desensitization by α,β-methylene-ATP and blockade of α 1 receptors with prazosin completely abolishes the response to nerve stimulation. The physiological significance of these two components of the response is now more clear. The fast purinergic component of the contraction is required to coordinate the rapid emission of sperm into the urethra prior to ejaculation, while the sustained noradrenergic contraction presumably prevents any reflux into the vas deferens during ejaculation.
Receptors for extracellular ATP can been divided into two categories: P2X receptors, which are ligand-gated ion channels involved in fast signaling; and P2Y receptors, which couple via heterotrimeric G proteins to a number of different biochemical pathways. Seven different P2X receptor subunits, P2X [1] [2] [3] [4] [5] [6] [7] , have been identified by molecular cloning techniques. The number of subunits needed to combine together to form a functional receptor is still not clear. It is, however, known that while identical subunits can co-assemble to form homomeric receptors, some subunits will assemble with other members of the family to form heteromeric receptors with novel properties (see [4] ). Molecular and immunohistochemical studies suggest that the predominant isoform present on smooth muscle cells is the P2X 1 receptor. Furthermore, electrophysiological and pharmacological studies have shown great similarity between the receptors present in smooth muscle and P2X 1 receptors expressed in recombinant systems.
In many early studies, desensitization of P2X receptors was the most effective way of abolishing responses. Subsequently, a number of antagonists including suramin, reactive blue 2 and pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid (PPADS) were discovered. These compounds lack potency and selectivity, however, and while effective on isolated cells, they are usually much less effective in intact tissues or in vivo. More recently TNP-ATP and Ip 5 I have been found to be very potent antagonists at some subtypes of P2X receptor [7, 8] , although again they appear to be much less active in intact tissues. The increasing interest of pharmaceutical companies in purinoceptor pharmacology should lead to the development of a new generation of antagonists, with greater potency, selectivity and activity in vivo.
Will a P2X 1 antagonist work as a contraceptive in man?
The idea of a P2X 1 receptor antagonist acting as a nonhormonal male contraceptive is very attractive, but the effectiveness of such a drug in man is by no means certain. There is considerable species variation in the properties, distribution and physiological role of P2X receptors. For example, the neurogenic contraction of the urinary bladder of the rat involves a large purinergic component, while in healthy humans it is almost entirely cholinergic (see [9] ). The relative importance of purinergic transmission in the human vas deferens in vivo is far from clear. While early in vitro studies failed to demonstrate a clear purinergic component in the human vas deferens, it should be remembered that these experiments were carried out on tissue samples obtained from elective vasectomy, and probably came from the more epidymal end of the organ. In the rat, the purinergic component of the neurogenic response is much greater in the prostatic than epidymal region of the tissue.
In a more recent study of the human vas deferens, a nonadrenergic component was identified [10] . A considerable part of the observed contraction was, however, resistant to the sodium channel blocker tetrodotoxin, indicating that it resulted from the direct stimulation of the smooth muscle. Thus, if there is a purinergic component, it may be quite small. On the other hand, oligospermia is not a recognized side effect of treatment with α 1 antagonists such as prazosin, which might be an indication that non-adrenergic neurotransmission is important for the emission of sperm in man. Thus, there is at present considerable uncertainty in the extrapolation from experimental animals to human clinical practice. It may transpire that a combination of a P2X 1 and an α 1 antagonist is required to inhibit emission sufficiently to produce infertility in man.
Would there be side effects? P2X 1 receptors are quite widely distributed on smooth muscle cells, including those of blood vessels and the urinary tract. Furthermore, messenger RNA for the P2X 1 receptor has been detected in autonomic and sensory ganglia and in the spinal cord. But evidence for functional P2X 1 receptors in neurons is still lacking. With such a widespread distribution of P2X 1 receptors, one might anticipate that the use of a selective antagonist would produce unwanted effects. Mice lacking these receptors are described as generally healthy, however,
Figure 1
Neurotransmission in the vas deferens. When the nerve action potential invades the terminal varicocities, vesicles containing the neurotransmitters noradrenaline (NA) and adenosine 5′-triphosphate (ATP) exocytose their contents into the junctional cleft between the axon and the smooth muscle cells. ATP binds to P2X 1 receptors (which are ligand-gated ion channels) to produce a rapid depolarization (the excitatory junction potential), giving rise to a rapid, though short-lived, contraction. Noradrenaline activates α 1 receptors to produce a slower but more sustained contraction through the release of Ca 2+ from intracellular stores. The mechanical response of the vas deferens to electrical field stimulation (EFS) with trains of electrical pulses varies slightly between species and with the stimulation frequency. In general it consists of a rapid contraction which quickly reaches a peak and then subsides to a lower level. When the α 1 receptors are blocked by the antagonist prazosin, the time course of the quickly activating and rapidly declining purinergic response is revealed, while desensitization of the P2X 1 receptors by the stable ATP analogue α,β-methylene-ATP exposes the slower and more sustained response mediated by noradrenaline. Combination of both treatments completely abolishes the response to nerve stimulation.
with no evidence of increased mortality in utero, but a slight elevation in systolic blood pressure.
While the apparent health of P2X 1 receptor-deficient mice might imply that purinergic systems are unimportant, a more likely explanation is that there are changes in other, parallel neurotransmitter systems which compensate for the lack of purinergic signaling. For example, in the P2X 1 knockout mice, the sensitivity of the vas deferens to noradrenaline is enhanced, leading to an increase in the size of the noradrenergic component of the response to nerve stimulation [5] . The effects of acute treatment with a selective P2X 1 antagonist may be quite different. One might predict in the absence of up-regulation of other transmitter systems, there would be both a greater contraceptive efficacy and more side effects.
Our understanding of native P2X receptors has been hampered by the lack of good pharmacological tools, and while growing rapidly it is still relatively naïve. Some P2X receptors are heteromeric, incorporating different P2X subunits. Furthermore, some of the subunits occur as splice variants, thus increasing further the scope for molecular and pharmacological diversity. An additional level of complexity arises from observations that, in some tissues, more than one type of P2X receptor are present on the same cell [11, 12] . With this great potential for diversity amongst native P2X receptors, there may well be scope for P2X antagonists specific for the receptors present on the vas deferens with minimal side effects.
In conclusion, the application of molecular genetics to the field of purinoceptor research has provided conclusive evidence for an important physiological role for purinergic signaling in the mouse, and raises the possibility of a novel approach to the regulation of male fertility. Whether this approach can be developed into an effective clinical treatment remains to be seen.
